- Home
- MPV vs ACRS Comparison
MPV vs ACRS Comparison
Compare MPV & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPV
- ACRS
- Stock Information
- Founded
- MPV 1988
- ACRS 2012
- Country
- MPV United States
- ACRS United States
- Employees
- MPV N/A
- ACRS N/A
- Industry
- MPV Finance Companies
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- MPV Finance
- ACRS Health Care
- Exchange
- MPV Nasdaq
- ACRS Nasdaq
- Market Cap
- MPV 201.1M
- ACRS 165.7M
- IPO Year
- MPV N/A
- ACRS 2015
- Fundamental
- Price
- MPV $20.25
- ACRS $1.84
- Analyst Decision
- MPV
- ACRS Strong Buy
- Analyst Count
- MPV 0
- ACRS 9
- Target Price
- MPV N/A
- ACRS $9.25
- AVG Volume (30 Days)
- MPV 25.2K
- ACRS 815.1K
- Earning Date
- MPV 01-01-0001
- ACRS 11-05-2025
- Dividend Yield
- MPV 8.71%
- ACRS N/A
- EPS Growth
- MPV N/A
- ACRS N/A
- EPS
- MPV 1.71
- ACRS N/A
- Revenue
- MPV N/A
- ACRS $16,789,000.00
- Revenue This Year
- MPV N/A
- ACRS N/A
- Revenue Next Year
- MPV N/A
- ACRS N/A
- P/E Ratio
- MPV $9.35
- ACRS N/A
- Revenue Growth
- MPV N/A
- ACRS N/A
- 52 Week Low
- MPV $11.18
- ACRS $1.05
- 52 Week High
- MPV $16.42
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- MPV 59.95
- ACRS 47.21
- Support Level
- MPV $19.10
- ACRS $2.01
- Resistance Level
- MPV $20.46
- ACRS $2.16
- Average True Range (ATR)
- MPV 0.37
- ACRS 0.11
- MACD
- MPV 0.03
- ACRS -0.03
- Stochastic Oscillator
- MPV 84.56
- ACRS 14.86
About MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.